This HTML5 document contains 144 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/pubchem-substance/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/iuphar/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/drugbank/
n10http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/guide-to-pharmacology/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/national-drug-code-directory/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n7http://www.drugs.com/
n21http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n11http://www.rxlist.com/cgi/generic/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/property/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00737/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00737
rdf:type
n3:Drug
n3:description
A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness. [PubChem]
n3:dosage
n18:271B530B-363D-11E5-9242-09173F13E4C5 n18:271B5308-363D-11E5-9242-09173F13E4C5 n18:271B5309-363D-11E5-9242-09173F13E4C5 n18:271B530A-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
6 hours
n3:indication
For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.
n3:manufacturer
n8:271B52F8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00737 n21:DB00737
dcterms:title
Meclizine
adms:identifier
n17:Meclizine n20:46507782 n22:3894 n23:2757 n24:2757 n25:DB00737 n26:PA450338 n27:4034 n28:C07116 n29:0662-2100-66
n3:mechanismOfAction
Along with its actions as an antagonist at H<sub>1</sub>-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone.
n3:packager
n8:271B52F7-363D-11E5-9242-09173F13E4C5 n8:271B52ED-363D-11E5-9242-09173F13E4C5 n8:271B52EE-363D-11E5-9242-09173F13E4C5 n8:271B52EB-363D-11E5-9242-09173F13E4C5 n8:271B52EC-363D-11E5-9242-09173F13E4C5 n8:271B52E9-363D-11E5-9242-09173F13E4C5 n8:271B52EA-363D-11E5-9242-09173F13E4C5 n8:271B52E7-363D-11E5-9242-09173F13E4C5 n8:271B52E8-363D-11E5-9242-09173F13E4C5 n8:271B52F5-363D-11E5-9242-09173F13E4C5 n8:271B52F6-363D-11E5-9242-09173F13E4C5 n8:271B52F3-363D-11E5-9242-09173F13E4C5 n8:271B52F4-363D-11E5-9242-09173F13E4C5 n8:271B52F1-363D-11E5-9242-09173F13E4C5 n8:271B52F2-363D-11E5-9242-09173F13E4C5 n8:271B52EF-363D-11E5-9242-09173F13E4C5 n8:271B52F0-363D-11E5-9242-09173F13E4C5 n8:271B52DD-363D-11E5-9242-09173F13E4C5 n8:271B52DE-363D-11E5-9242-09173F13E4C5 n8:271B52DB-363D-11E5-9242-09173F13E4C5 n8:271B52DC-363D-11E5-9242-09173F13E4C5 n8:271B52D9-363D-11E5-9242-09173F13E4C5 n8:271B52DA-363D-11E5-9242-09173F13E4C5 n8:271B52D7-363D-11E5-9242-09173F13E4C5 n8:271B52D8-363D-11E5-9242-09173F13E4C5 n8:271B52E5-363D-11E5-9242-09173F13E4C5 n8:271B52E6-363D-11E5-9242-09173F13E4C5 n8:271B52E3-363D-11E5-9242-09173F13E4C5 n8:271B52E4-363D-11E5-9242-09173F13E4C5 n8:271B52E1-363D-11E5-9242-09173F13E4C5 n8:271B52E2-363D-11E5-9242-09173F13E4C5 n8:271B52DF-363D-11E5-9242-09173F13E4C5 n8:271B52E0-363D-11E5-9242-09173F13E4C5 n8:271B52CD-363D-11E5-9242-09173F13E4C5 n8:271B52CE-363D-11E5-9242-09173F13E4C5 n8:271B52CB-363D-11E5-9242-09173F13E4C5 n8:271B52CC-363D-11E5-9242-09173F13E4C5 n8:271B52C9-363D-11E5-9242-09173F13E4C5 n8:271B52CA-363D-11E5-9242-09173F13E4C5 n8:271B52C7-363D-11E5-9242-09173F13E4C5 n8:271B52C8-363D-11E5-9242-09173F13E4C5 n8:271B52D5-363D-11E5-9242-09173F13E4C5 n8:271B52D6-363D-11E5-9242-09173F13E4C5 n8:271B52D3-363D-11E5-9242-09173F13E4C5 n8:271B52D4-363D-11E5-9242-09173F13E4C5 n8:271B52D1-363D-11E5-9242-09173F13E4C5 n8:271B52D2-363D-11E5-9242-09173F13E4C5 n8:271B52CF-363D-11E5-9242-09173F13E4C5 n8:271B52D0-363D-11E5-9242-09173F13E4C5 n8:271B52BD-363D-11E5-9242-09173F13E4C5 n8:271B52BE-363D-11E5-9242-09173F13E4C5 n8:271B52BC-363D-11E5-9242-09173F13E4C5 n8:271B52C5-363D-11E5-9242-09173F13E4C5 n8:271B52C6-363D-11E5-9242-09173F13E4C5 n8:271B52C3-363D-11E5-9242-09173F13E4C5 n8:271B52C4-363D-11E5-9242-09173F13E4C5 n8:271B52C1-363D-11E5-9242-09173F13E4C5 n8:271B52C2-363D-11E5-9242-09173F13E4C5 n8:271B52BF-363D-11E5-9242-09173F13E4C5 n8:271B52C0-363D-11E5-9242-09173F13E4C5
n3:synonym
Meclizine Nevidoxine Meclozine
n3:toxicity
Symptoms of overdose include drowsiness and anticholinergic effects. LD<sub>50</sub>=mg/kg (orally in rat).
n9:hasAHFSCode
n10:56-22-08
n3:foodInteraction
Take with food to reduce irritation. Avoid alcohol.
n3:mixture
n19:271B52BA-363D-11E5-9242-09173F13E4C5 n19:271B52BB-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
U.S. Patent 2,709,169.
foaf:page
n7:meclizine.html n11:mecliz.htm
n3:IUPAC-Name
n5:271B5310-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5316-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5315-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5312-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5313-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5314-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5325-363D-11E5-9242-09173F13E4C5 n5:271B530E-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5327-363D-11E5-9242-09173F13E4C5 n5:271B530F-363D-11E5-9242-09173F13E4C5 n5:271B530C-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B530D-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n14:R06AE05
n3:H-Bond-Acceptor-Count
n5:271B531C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B531D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5317-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5318-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B531A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5319-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B531B-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
569-65-3
n3:category
n3:containedIn
n15:271B52FC-363D-11E5-9242-09173F13E4C5 n15:271B52FD-363D-11E5-9242-09173F13E4C5 n15:271B52FA-363D-11E5-9242-09173F13E4C5 n15:271B52FB-363D-11E5-9242-09173F13E4C5 n15:271B5305-363D-11E5-9242-09173F13E4C5 n15:271B5306-363D-11E5-9242-09173F13E4C5 n15:271B5303-363D-11E5-9242-09173F13E4C5 n15:271B5304-363D-11E5-9242-09173F13E4C5 n15:271B52F9-363D-11E5-9242-09173F13E4C5 n15:271B5307-363D-11E5-9242-09173F13E4C5 n15:271B5301-363D-11E5-9242-09173F13E4C5 n15:271B5302-363D-11E5-9242-09173F13E4C5 n15:271B52FF-363D-11E5-9242-09173F13E4C5 n15:271B5300-363D-11E5-9242-09173F13E4C5 n15:271B52FE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5321-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5323-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5324-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5326-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5320-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B531F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5322-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5311-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B531E-363D-11E5-9242-09173F13E4C5